Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

551.49 +1.36 (+0.25%)
Streaming Delayed Price Updated: 2:09 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eli Lilly

< Previous 1 2 3 4 5 6 7 Next >
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout. 
Via MarketBeat
Exposures Product Safety
Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Eli Lilly, Genentech, BioNTech, Xencor, Celgene
Via AB Newswire
Exposures Product Safety
Alopecia Market expected to rise | Companies – Stiefel, GlaxoSmithKline, Eli Lilly and Company, Incyte Corporation, Energenesis Biomedical Co., expected to drive market
Via AB Newswire
Inflammatory Bowel Disease Market expected to rise | Companies – Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, expected to drive market
Via AB Newswire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Names New COO, Announces Participation in Upcoming London Symposium
Via Investor Brand Network
Exposures Product Safety
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June. 
Via MarketBeat
Promising Small Biotech Amphastar Sees Actionable Pullback
Small-cap Amphastar Pharmaceuticals is pulling back from recent highs in an orderly fashion, potentially offering a new entry point after beating Q1 views. 
Via MarketBeat
Chronic Kidney Disease Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 76+ Companies are working to improve the Treatment of Space | Eli Lilly and Company, Reata Pharma, Novo Nordisk
Via AB Newswire
Eli Lilly and Company (NYSE: LLY) Records 52-Week High Monday Morning
Via Investor Brand Network
Glioma Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Oncorus, Evgen Pharma, OncoSynergy, Inc., Eli Lilly and Company, Erasca, Inc
Via AB Newswire
Exposures Product Safety
Eli Lilly and Company (NYSE: LLY) Highlighted for Surprising Price Action
Via Investor Brand Network
Eli Lilly and Company (NYSE: LLY) Climbs to New 52-Week High
Via Investor Brand Network
Smartsheet Investors’ Hasty Exit Can Be Your Gain
Enterprise workflow collaboration and automation software maker Smartsheet Inc. (NASDAQ: SMAR) shares plummeted over 20% due to its fiscal Q1 2024 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover
The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer. 
Via MarketBeat
Ulcerative Colitis Market to Register Sustainable Growth During the Forecast Period (2023-2032) – DelveInsight | InDex, EA Pharma, Theravance, Janssen, Lycera, LG Chem, Iltoo Pharma, Immunic, Tianjin
Via AB Newswire
Neuroblastoma Market to witness growth by 2032, estimates DelveInsight | Aptorum, Athenex, Eli Lilly, Clarity Pharmaceuticals, Y-mAbs Therapeutics Inc, Novartis AG, Bristol-Myers Squibb, Roche
Via AB Newswire
Eli Lilly (NYSE: LLY) Acquires DICE Therapeutics (NASDAQ: DICE): A New Step in Autoimmune Disease Treatments
Via Spotlight Growth
Alopecia Areata Market Analysis, Growth Opportunities, Clinical Trials Assessment, Emerging Therapies, Leading Companies, and Epidemiology Forecast | Arcutis, Concert Pharmaceutical, HCW Biologics
Via AB Newswire
Biologics and Biosimilars Market Is Touching New Level – A Comprehensive Study with Key Players Amgen, AbbVie, Sanofi-Aventis
Biologics and Biosimilar Market Size, Status and Forecast 2028 
Via SBWire
Topics Intellectual Property
Exposures Intellectual Property
Mantle Cell Lymphoma Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – AbbVie, BeiGene, Genentech, Incyte, Janssen, Nurix, Takeda
Via AB Newswire
Obstructive Sleep Apnea Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Takeda, Bayer, Apnimed, Desitin Arzneimittel GmbH, Eli Lilly, Jazz Pharma
Via AB Newswire
Exposures Product Safety
Septic Shock Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | AstraZeneca, Eli Lilly and Company, La Jolla Pharma, Vivacelle Bio
Via AB Newswire
Bullish or Bearish? Vetting Animal Health Care Stocks
Americans are paying more and more attention to pet health, making pet care stocks look healthy again. Here are two names worth a check up. 
Via MarketBeat
Topics ETFs
Neuroblastoma Pipeline, NDA Approvals, Emerging Drugs, and Clinical Trials (2023) | Companies – Clarity Pharmaceuticals, Y mAbs Therapeutics, Nova Biopharma, Eli Lilly and Company, GE Healthcare
Via AB Newswire
Nephroblastoma Pipeline, NDA Approvals, Clinical Trials, and Emerging Drugs (2023) | Companies – Clarity Pharma, Y mAbs Therapeutics, Nova Biopharma, Eli Lilly, Illumina Radiopharma, Recombio and Other
Via AB Newswire
Ocular Melanoma Market expected to rise | Companies – Eli Lilly & Co, Spectrum Pharmaceuticals Inc, Novartis AG, Bayer, AstraZeneca plc, Merck, Amgen, Pfizer Inc, Roche, expected to drive market
Via AB Newswire
Hagens Berman: Settlement Worth in Excess of $500 Million Reached in Insulin Pricing Class-Action Lawsuit
From Hagens Berman
Via Business Wire
Lifestyle Drugs Market to Eyewitness Massive Growth : Eli Lilly, Pfizer, BMS, AstraZeneca
Stay up-to-date with Lifestyle Drugs Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Exposures Product Safety
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth. 
Via MarketBeat
Topics Economy
Exposures Economy
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside. 
Via MarketBeat
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.